Radspherin is under clinical development by Oncoinvent and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I drugs for Peritoneal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Radspherin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Radspherin, is under development for the treatment of metastatic cancers including peritoneal carcinomatosis originating from ovarian cancer, fallopian cancer, peritoneal cancer and colorectal cancer. It constitutes a monoclonal antibody OI-3 conjugated to a radioisotope or toxin. The drug candidate is a suspension of inorganic alpha-emitting radioactive microspheres and administered as intraperitoneal injection. It acts by targeting CD146 antigen.
Oncoinvent is a monoclonal antibodies product manufacturer. The company develops and manufactures therapeutic product for the treatment of various cancer. It develops Radspherin technology, an alpha-emitting radioactive microsphere, which is designed for treatment of metastatic cancers in body cavities. Oncoinvent’s Radspherin technology is an anticipated that the product can potentially treat several forms of metastatic cancer, ovarian cancer and colorectal cancer. It platforms through injections, medicines and liquids. The company carters its products under the brand Radspherin. Oncoinvent is headquartered in Oslo city, Oslo, Norway.
For a complete picture of Radspherin’s drug-specific PTSR and LoA scores, buy the report here.